title: Pigmented villonodular synovitis therapy with MSCF-1 inhibitors.
abstract: OBJECTIVE
  Giant cell tumor of tendon sheath and pigmented villonodular synovitis are synovial-based diseases that are generally treated by surgery. For aggressive and recurrent tumors, treatment alternatives are needed. This review explores a targeted therapeutic strategy.
  
  
  RESULTS
  Imatinib, a tyrosine kinase inhibitor, blocks expression of colony stimulating factor 1 (CSF1) by a small subpopulation of tumor cells that recruit CSF1-bearing nonneoplastic cells. Limited clinical data support the efficacy and side effect profile of imatinib in stabilizing disease in most patients.
  
  
  CONCLUSIONS
  Imatinib along with other such inhibitors and monoclonal antibodies to CSF1R are putative drugs that may play an important role in the treatment of these tumors.
authors.affiliation: Department of Orthopaedic Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA. htemple@med.miami.edu
authors.forename: H Thomas
authors.initials: HT
authors.lastname: Temple
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D016173:Macrophage Colony-Stimulating Factor / Q000037:antagonists & inhibitors* / Q000276:immunology; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D016186:Receptor, Macrophage Colony-Stimulating Factor / Q000276:immunology; D013586:Synovitis, Pigmented Villonodular / Q000188:drug therapy* / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D016173:Macrophage Colony-Stimulating Factor; D000068877:Imatinib Mesylate; D016186:Receptor, Macrophage Colony-Stimulating Factor